drugset / Trial / NCT06170827
Study to Evaluate the AIO-001 in Healthy Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This goal of the open-label single dose study is to evaluate and compare the safety, tolerability, pharmacokinetic (PK), and immunogenicity of AIO-001 using two different formulations in 16 healthy volunteers.
Timeline
- Start
- 2023-11-21
- Primary completion
- 2024-07-15
- Completion
- 2024-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AIO-001 | Unknown | 400 mg | Subcutaneous |